Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I–II trial

Our purpose was to determine the efficacy of irinotecan plus paclitaxel administered on day 1, repeated every 2 weeks, in untreated patients with advanced or metastatic non-small-cell lung cancer (NSCLC). In total, 56 patients with inoperable or metastatic stage III and IV NSCLC with a histologicall...

Descripción completa

Detalles Bibliográficos
Autores principales: Stathopoulos, G P, Dimitroulis, J, Antoniou, D, Katis, C, Tsavdaridis, D, Armenaki, O, Marosis, C, Michalopoulou, P, Grigoratou, T, Stathopoulos, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361499/
https://www.ncbi.nlm.nih.gov/pubmed/16251879
http://dx.doi.org/10.1038/sj.bjc.6602827

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361499/
https://www.ncbi.nlm.nih.gov/pubmed/16251879
http://dx.doi.org/10.1038/sj.bjc.6602827

Ejemplares similares